Pharvaris price target raised to $65 by Leerink Partners
Leerink Partners raised its Pharvaris price target to $65.00 per share from $50.00 and maintained an Outperform rating, per TradingView News via Benzinga.
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.